Last $55.86 USD
Change Today 0.00 / 0.00%
Volume 0.0
ALNY On Other Exchanges
Symbol
Exchange
NASDAQ GS
Frankfurt
As of 8:10 PM 07/23/14 All times are local (Market data is delayed by at least 15 minutes).

Executive Profile*

Laurence E. Reid Ph.D.

Chief Business Officer and Senior Vice President, Alnylam Pharmaceuticals, Inc.
AgeTotal Calculated CompensationThis person is connected to 0 board members in 0 different organizations across 2 different industries.

50$1,213,586
As of Fiscal Year 2013

Background*

Dr. Laurence E. Reid, Ph.D., has been Chief Business Officer and Senior Vice President at Alnylam Pharmaceuticals, Inc. since June 2010. Dr. Reid served as Chief Business Officer at Ensemble Therapeutics Corporation(also known as Ensemble Discovery Corporation) since March 2006 and served as its Head of Business Development and Corporate Development. Dr. Reid has over 20 years of diverse business and science experience in the life sciences field. His experience includes ...

Read Full Background

Corporate Headquarters*

300 Third Street
Cambridge, Massachusetts 02142

United States

Phone: 617-551-8200
Fax: 617-551-8101

Board Members Memberships*

There is no Board Members Memberships data available.

Education*

BA
University of Cambridge
PhD
University Of London

Other Affiliations*

Annual Compensation*

Salary$375,000
Bonus$25,000
Total Annual Compensation$400,000

Stock Options*

All Other Compensation$7,182
Exercised Options27,252
Exercised Options Value$890,484
Exercisable Options176,565
Unexercisable Options98,772
Total Value of Options$890,484
Total Number of Options322,589

Total Compensation*

Total Annual Cash Compensation$568,432
Total Short Term Compensation$400,000
Other Long Term Compensation$7,182
Total Calculated Compensation$1,213,586
*Data is at least as current as the most recent Definitive Proxy.
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
ALNY:US $55.86 USD 0.00

COMPETITOR COMPENSATION

NamePosition/
Company
Compensation
Ali Mortazavi Chief Executive and Director
Silence Therapeutics plc
70.0K GBP
Hans G. C. P. Schikan Chief Executive Officer and Member of Management Board
Prosensa Holding N.V.
--
Mark J. Ahn Ph.D.Chief Executive Officer, President and Director
Galena Biopharma, Inc.
$737.0K
Mark J. Murray Ph.D.Chief Executive Officer, President and Director
Tekmira Pharmaceuticals Corporation
$377.5K
Kleanthis G. Xanthopoulos Ph.D.Chief Executive Officer, President, Principal Financial & Accounting Officer and Director
Regulus Therapeutics Inc.
$600.0K
Compensation as of Fiscal Year 2013.

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ALNYLAM PHARMACEUTICALS INC, please visit . Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.